tpoxx
tpoxx: developed by 1 company · 2 FDA decisions. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | Approved |
FDA Decisions
Frequently asked questions
Who is developing tpoxx?
tpoxx is being developed by SIGA TECHNOLOGIES INC.
What is tpoxx's latest FDA decision?
The most recent tracked FDA decision for tpoxx is Approval for 1 INDICATIONS AND USAGE TPOXX is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg. ( 1.1 ) Limitations of Use: The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( , dated May 18, 2022.
Get deeper analysis on tpoxx
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis